Nanomedicine News

RSS

Sorrento to Present Data on Cynviloq-Abraxane PK Study for Ovarian Cancer

Sorrento Therapeutics, Inc. (Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that it will present data on the comparison of Cynviloq™ and Abraxane® (nab-paclitaxel) pharmacokinetics (PK) from animal studies.

7 Apr 2014

Lasers Trigger Nanoballoons to Release Drugs

Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go.

4 Apr 2014

Controlled Rotation of Magnetic Nanoparticles Could Force Tumour Cells to 'Self-Destruct'

Using magnetically controlled nanoparticles to force tumour cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden.

4 Apr 2014

Baxter to Acquire Chatham’s Hemophilia Developmental Gene Therapy Programs

Baxter International Inc. and Chatham Therapeutics, LLC, today announced that Baxter has agreed to acquire all of Chatham’s outstanding membership interests. As a result of the transaction, Baxter will acquire Chatham’s developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia.

4 Apr 2014

Rexahn to Present Poster on RX-21101 Nano-Polymer-Drug Conjugate Systems at AACR Meeting

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it will have two poster presentations at the 2014 American Association for Cancer Research (AACR) Annual Meeting. The conference will take place in San Diego, California, on April 5-9, 2014 at the San Diego Convention Center.

3 Apr 2014

Tekmira Reports Positive Results of LNP Technology at Symposium of Filoviruses

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, announced that recent advances in its anti-viral product platform were presented at the 6th International Symposium of Filoviruses, which is taking place in Galveston, Texas from March 30 to April 2, 2014.

3 Apr 2014

pSivida’s Nanotechnology-Based Tethadur Sustained-Release Delivery System to be Discussed at World Ophthalmology Conference

pSivida Corp. , a leader in the development of sustained release products for treating eye diseases, today announced that pSivida’s president and chief executive officer, Dr. Paul Ashton, will discuss pSivida’s Tethadur™ technology designed to provide sustained delivery of biologics at The World Ophthalmology Conference in Tokyo, April 2-6 and at the SMi Inaugural Conference on Biosimilars and Biobetters USA, in Iselin, New Jersey, April 7-8.

From EyePoint Pharmaceuticals, Inc. 2 Apr 2014

New Mechanism Utilizes Light to Activate Drug-Delivering Nanoparticles

Researchers from the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, in collaboration with materials scientists, engineers and neurobiologists, have discovered a new mechanism for using light to activate drug-delivering nanoparticles and other targeted therapeutic substances inside the body.

2 Apr 2014

NanoViricides’ President Honored as ‘Researcher of the Year’

NanoViricides, Inc. (the “Company”) announced today that Anil R. Diwan, Ph.D., President, Chairman, and co-Founder of the Company was recognized as the “2014 Researcher of the Year” by BusinessNewHaven, a business journal, and New Haven Magazine, publications that serve the state of Connecticut.

From NanoViricides, Inc 1 Apr 2014

Enrollment Begins for MF 1001 NanoTherm Therapy Study for Glioblastoma Treatment

MagForce AG (Frankfurt, Xetra: MF6), a leading medical technology company in the area of nanotechnology which focuses on oncology, today announced the enrollment of the first patient in the MF 1001 clinical study. MF 1001 is an open-label, randomized, controlled clinical trial assessing the efficacy and safety of NanoTherm® therapy as monotherapy and in combination with radiotherapy compared to radiotherapy alone in glioblastoma patients at first relapse.

From MagForce Nanotechnologies AG 1 Apr 2014

Nanomedicine News

Sorrento to Present Data on Cynviloq-Abraxane PK Study for Ovarian Cancer

Lasers Trigger Nanoballoons to Release Drugs

Controlled Rotation of Magnetic Nanoparticles Could Force Tumour Cells to 'Self-Destruct'

Baxter to Acquire Chatham’s Hemophilia Developmental Gene Therapy Programs

Rexahn to Present Poster on RX-21101 Nano-Polymer-Drug Conjugate Systems at AACR Meeting

Tekmira Reports Positive Results of LNP Technology at Symposium of Filoviruses

pSivida’s Nanotechnology-Based Tethadur Sustained-Release Delivery System to be Discussed at World Ophthalmology Conference

New Mechanism Utilizes Light to Activate Drug-Delivering Nanoparticles

NanoViricides’ President Honored as ‘Researcher of the Year’

Enrollment Begins for MF 1001 NanoTherm Therapy Study for Glioblastoma Treatment

Enhancing Material Properties through Nanotube Encapsulation

Sustainable Carbon Nanomaterial Gii Set to Transform Energy Storage in Internet of Things Devices

Brain-Inspired Nano-Tech Promises New Era for Electronics

Breakthrough in 2D Material Growth Opens Doors to Cleaner Energy and Next-Generation Technology

Sustainable Future for Carbon Nanotubes

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Conversations on AFM: Applications of BioAFM in Life Science

Sponsored Content

Characterization of Active Pharmaceutical Ingredients, Injectables, and Proteins

The Future of Wound Care: Why Nanofibers are Key to Accelerated Healing

The Evolution of Lipid Nanoparticles

How Emulsion Electrospinning is Transforming Materials